[1] Nauck MA, Baller JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type diabetes[J].Diabetes,2004, 53 (Suppl 3): S190-S195. [2] 周宗爱,陈年由,汤智越,等.西格列汀治疗2 型糖尿病的临床疗效及其对血清葡萄糖转运蛋白4 的影响[J].中国临床药理学杂志,2015,14(7):491-494. [3] Takeda Y, Fujita Y, Honjo J,et al. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice[J].Diabetologia,2012, 55(2) : 404-412. [4] Yeom JA, Kim ES, Park HS. et al. Both sitagliptin analogue & pioglitazone preserve the Beta-cell proportion in the islets with different mechanism in non- obese and obese diabetic mice[J].BMB Rep,2011, 44(11) : 713-718. [5] 史存才.甘精胰岛素联合瑞格列奈治疗2 型糖尿病的临床效果观察[J].中国当代医药,2014,21(16) :99-101. [6] 黄家庆,徐衡,黄家哗,等.甘精胰岛素联合瑞格列奈治疗老年脆性2型糖尿病[J].基层医学论坛,2013,17(7):837-839. [7] Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin inpatients with type 2 diabetes[J].Diabetes Obes Metab,2010, 12(1): 1-10. [8] Hong ES,Khang AR,Yoon JW,et al.Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study[J].Diabetes Obes Metab,2012,14( 9) : 795-802.
2019, Vol. 36 
